| Excess TGF-β mediates muscle weakness associated with bone metastases in mice DL Waning, KS Mohammad, S Reiken, W Xie, DC Andersson, S John, ... Nature medicine 21 (11), 1262-1271, 2015 | 359 | 2015 |
| Chemotherapy-related cachexia is associated with mitochondrial depletion and the activation of ERK1/2 and p38 MAPKs R Barreto, DL Waning, H Gao, Y Liu, TA Zimmers, A Bonetto Oncotarget 7 (28), 43442, 2016 | 192 | 2016 |
| Requirements for budding of paramyxovirus simian virus 5 virus-like particles AP Schmitt, GP Leser, DL Waning, RA Lamb Journal of virology 76 (8), 3952-3964, 2002 | 186 | 2002 |
| Assessment of muscle mass and strength in mice A Bonetto, DC Andersson, DL Waning BoneKEy reports 4, 2015 | 130 | 2015 |
| Molecular mechanisms of bone metastasis and associated muscle weakness DL Waning, TA Guise Clinical Cancer Research 20 (12), 3071-3077, 2014 | 106 | 2014 |
| Roles for the cytoplasmic tails of the fusion and hemagglutinin-neuraminidase proteins in budding of the paramyxovirus simian virus 5 DL Waning, AP Schmitt, GP Leser, RA Lamb Journal of virology 76 (18), 9284-9297, 2002 | 97 | 2002 |
| Activation of a paramyxovirus fusion protein is modulated by inside-out signaling from the cytoplasmic tail DL Waning, CJ Russell, TS Jardetzky, RA Lamb Proceedings of the National Academy of Sciences 101 (25), 9217-9222, 2004 | 88 | 2004 |
| Role of TGF-β in breast cancer bone metastases A Chiechi, DL Waning, KR Stayrook, JT Buijs, TA Guise, KS Mohammad Advances in bioscience and biotechnology (Print) 4 (10C), 15, 2013 | 81 | 2013 |
| Bone-induced expression of integrin β3 enables targeted nanotherapy of breast cancer metastases MH Ross, AK Esser, GC Fox, AH Schmieder, X Yang, G Hu, D Pan, X Su, ... Cancer research 77 (22), 6299-6312, 2017 | 73 | 2017 |
| Chemotherapy‐induced loss of bone and muscle mass in a mouse model of breast cancer bone metastases and cachexia BA Hain, H Xu, JR Wilcox, D Mutua, DL Waning JCSM Rapid communications 2 (1), 1-12, 2019 | 48 | 2019 |
| Controlling the Mdm2-Mdmx-p53 Circuit DL Waning, JA Lehman, CN Batuello, LD Mayo Pharmaceuticals 3 (5), 1576-1593, 2010 | 47 | 2010 |
| Combination therapy in a xenograft model of glioblastoma: enhancement of the antitumor activity of temozolomide by an MDM2 antagonist H Wang, S Cai, BJ Bailey, MR Saadatzadeh, J Ding, E Tonsing-Carter, ... Journal of neurosurgery 126 (2), 446-459, 2017 | 46 | 2017 |
| The role of TGFβ in bone-muscle crosstalk JN Regan, T Trivedi, TA Guise, DL Waning Current osteoporosis reports 15, 18-23, 2017 | 42 | 2017 |
| Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in vivo LE Wright, AA Harhash, WM Kozlow, DL Waning, JN Regan, Y She, ... Oncotarget 8 (5), 8406, 2017 | 38 | 2017 |
| c-Abl phosphorylation of Mdm2 facilitates Mdm2-Mdmx complex formation DL Waning, JA Lehman, CN Batuello, LD Mayo Journal of biological chemistry 286 (1), 216-222, 2011 | 38 | 2011 |
| Zoledronic acid improves muscle function in healthy mice treated with chemotherapy BA Hain, B Jude, H Xu, DM Smuin, EJ Fox, JC Elfar, DL Waning Journal of Bone and Mineral Research 35 (2), 368-381, 2020 | 36 | 2020 |
| Induction of apoptotic genes by a p73-phosphatase and tensin homolog (p73-PTEN) protein complex in response to genotoxic stress JA Lehman, DL Waning, CN Batuello, R Cipriano, MP Kadakia, LD Mayo Journal of Biological Chemistry 286 (42), 36631-36640, 2011 | 36 | 2011 |
| Cul4A is required for hematopoietic cell viability and its deficiency leads to apoptosis DL Waning, B Li, N Jia, Y Naaldijk, WS Goebel, H HogenEsch, KT Chun Blood, The Journal of the American Society of Hematology 112 (2), 320-329, 2008 | 34 | 2008 |
| Cancer-associated muscle weakness: What's bone got to do with it? DL Waning, TA Guise BoneKEy reports 4, 2015 | 33 | 2015 |
| Osteolytic breast cancer causes skeletal muscle weakness in an immunocompetent syngeneic mouse model JN Regan, C Mikesell, S Reiken, H Xu, AR Marks, KS Mohammad, ... Frontiers in Endocrinology 8, 358, 2017 | 31 | 2017 |
